Cargando…

Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report

BACKGROUND: Refractory pouchitis is a common cause of pouch failure, which may require surgical excision of the pouch or permanent diversion. We aimed to show the effect of vedolizumab on treatment of the patient with refractory pouchitis. CASE SUMMARY: A 32-year-old male with pancolonic ulcerative...

Descripción completa

Detalles Bibliográficos
Autor principal:	Cakir, Ozlem Ozer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718792/ https://www.ncbi.nlm.nih.gov/pubmed/31531325 http://dx.doi.org/10.12998/wjcc.v7.i16.2316

Ejemplares similares

Vedolizumab for chronic antibiotic-refractory pouchitis
por: Singh, Amandeep, et al.
Publicado: (2019)

Use of vedolizumab in a patient with chronic and refractory pouchitis
por: Orfanoudaki, Eleni, et al.
Publicado: (2018)

Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis
por: Bethge, Johannes, et al.
Publicado: (2017)

Association between serum tumor necrosis factor-alpha level and the efficacy of infliximab for refractory pouchitis after restorative proctocolectomy in patients with ulcerative colitis
por: Uchino, Motoi, et al.
Publicado: (2018)

α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis
por: Melde, Michaela, et al.
Publicado: (2021)

Chronic Antibiotic-Refractory Pouchitis: Management Challenges
por: Outtier, An, et al.
Publicado: (2021)

Pouchitis.
por: Schouten, W R
Publicado: (1998)

Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent
por: Yeates, Jessica, et al.
Publicado: (2010)

One-year infliximab administration for the treatment of chronic refractory pouchitis
por: Viazis, Nikos, et al.
Publicado: (2011)

Alicaforsen: An Emerging Therapeutic Agent for Ulcerative Colitis and Refractory Pouchitis
por: Hosten, Terron Anthony, et al.
Publicado: (2014)

Hyperbaric oxygen therapy for chronic antibiotic-refractory ischemic pouchitis
por: Nyabanga, Custon T, et al.
Publicado: (2017)

Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or Vedolizumab
por: Chiorean, Michael, et al.
Publicado: (2020)

Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
por: Lukin, Dana, et al.
Publicado: (2020)

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review
por: Helwig, Ulf, et al.
Publicado: (2020)

The role of antibiotics and probiotics in pouchitis
por: Gionchetti, Paolo, et al.
Publicado: (2012)

Ileal Pouchitis With Endoscopic Pictures
por: Ali, Hassam, et al.
Publicado: (2021)

Pyoderma gangrenosum associated with chronic refractory pouchitis: a case successfully treated with infliximab
por: Koumaki, Dimitra, et al.
Publicado: (2020)

Vedolizumab Therapy in Refractory Enteropathy Associated With CVID
por: Johnson, Dane, et al.
Publicado: (2021)

Risk Factors Associated With Hospital Readmission and Costs for Pouchitis
por: Gonzalez, Adalberto, et al.
Publicado: (2021)

Alopecia secondary to anti-tumor necrosis factor-alpha therapy()
por: Ribeiro, Lara Beatriz Prata, et al.
Publicado: (2015)

Fecal microbiota in pouchitis and ulcerative colitis
por: Li, Kai-Yu, et al.
Publicado: (2016)

Pouchitis: Clinical Features, Diagnosis, and Treatment
por: Gionchetti, Paolo, et al.
Publicado: (2021)

Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases
por: Singh, Siddharth, et al.
Publicado: (2022)

Whipple’s disease diagnosed during anti-tumor necrosis factor alpha treatment: two case reports and review of the literature
por: Ramos, Jose M., et al.
Publicado: (2015)

Anti-tumor necrosis factor therapy in children with refractory Takayasu arteritis: report of five cases
por: Kostina, YO, et al.
Publicado: (2011)

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
por: Bohm, Matthew, et al.
Publicado: (2020)

Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use
por: Kang, Ho Suk, et al.
Publicado: (2019)

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis
por: Shen, Bo, et al.
Publicado: (2008)

Campylobacter Pouchitis Mimicking the Appearance of Crohn's Disease
por: Cohen, Greg S., et al.
Publicado: (2016)

Patient-Specific Bacteroides Genome Variants in Pouchitis
por: Vineis, Joseph H., et al.
Publicado: (2016)

Pouchitis Associated With Pelvic Radiation for Prostate Cancer
por: Kulkarni, Geeta, et al.
Publicado: (2016)

Diversion colitis and pouchitis: A mini-review
por: Tominaga, Kentaro, et al.
Publicado: (2018)

The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis
por: LeBlanc, Jean-Frédéric, et al.
Publicado: (2021)

Medical treatment of pouchitis: a guide for the clinician
por: Rabbenou, Wendy, et al.
Publicado: (2021)

Acute pouchitis: the condition that time forgot about
por: Segal, Jonathan P., et al.
Publicado: (2022)

#MondayNightIBD: Management of Chronic #Pouchitis
por: Donet, Jean A, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
por: Holko, Przemysław, et al.
Publicado: (2018)

Blockade of Tumor Necrosis Factor-Alpha: A Role for Adalimumab in Neovascular Age-Related Macular Degeneration Refractory to Anti-Angiogenesis Therapy?
por: Fernández-Vega, Beatriz, et al.
Publicado: (2016)

Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders
por: Pascual-Camps, Isabel, et al.
Publicado: (2014)

Paradoxical Side Effect Related With Anti-Tumor Necrosis Factor Alpha Treatment
por: Aşkın, Ayhan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8ls6j920npd1ln3kr6busc4834